Gastroparesis Drugs Market 2022 | North America accounted for a major share of 61.3%

According to a new report published by Allied Market Research, titled, Gastroparesis Drugs Market, by Drug Class, Disease Type, and End User: Global Opportunity Analysis and Industry Forecast, 2017-2023," the global gastroparesis market was valued at $4,667 million in 2016, and is projected to reach $6,486 million at a CAGR of 4.7% from 2017 to 2023.

Do Enquiry for Sample Report @ https://www.alliedmarketresearch.com/request-sample/4153
Key findings of the Gastroparesis Drugs Market:

Prokinetic agents segment accounted for more than four-fifths share of the global gastroparesis drugs market in 2016.
Botulinum toxin injection segment is expected to grow at a CAGR of 5.6% from 2017 to 2023.
Idiopathic gastroparesis segment accounted for around 34.9% share of the global gastroparesis drugs market in 2016.
Hospitals accounted for nearly two-fifths share of the global gastroparesis drugs market in 2016.
Pharmacies segment is expected to grow at a CAGR of 5.0% from 2017 to 2023

North America was the leading revenue contributor to the global gastroparesis drugs market, accounting for nearly one-third of the global market. This is attributed to the early approval of gastroparesis drugs and high use of these drugs due to rise in incidence of gastroparesis. However, Asia-Pacific is expected to grow at the highest CAGR of 5.5% during the study period, due to increase in affordability, surge in healthcare expenditure, and rise in awareness toward gastroparesis drugs.

Gastroparesis affects the normal spontaneous movement of the muscles of stomach and interferes with the normal digestion, thus causing nausea, vomiting, and problems related with blood sugar levels & nutrition. Gastroparesis is caused due to diabetes or can develop after surgery. Recently, advanced drugs such as metoclopramide, erythromycin, antiemetics, and others are developed to treat gastroparesis.

Key Market Segments

By Drug Class
Prokinetic Agents
Antiemetic Agents
Botulinum Toxin Injections
By Disease Type
Diabetic Gastroparesis
Idiopathic Gastroparesis
Post-surgical Gastroparesis
Others
BY DISTRIBUTION CHANNEL
Hospitals
Pharmacies
Clinics
E-commerce

Key Market Players

ABBOTT LABORATORIES (ABBOTT ARZNEIMITTEL GMBH)
ALLERGAN PLC
ASTRAZENECA PLC
CADILA PHARMACEUTICALS LIMITED
ETX PHARMA, INC.
EVOKE PHARMA, INC.
GLAXOSMITHKLINE PLC
NEUROGASTRX, INC.
THERAVANCE BIOPHARMA, INC.
VALEANT PHARMACEUTICAL INTERNATIONAL, INC.

The major factors that drive the growth of the global gastroparesis drugs market are rise in number of surgeries that may lead to postoperative gastroparesis, increase in diabetic population, introduction of novel drugs, and surge in geriatric population. However, side effects associated with gastroparesis drugs and time-consuming regulatory approvals are expected to restrain the market growth. Conversely, huge untapped market potential in the emerging countries, such as China and India, and development of novel gastroparesis drugs are expected to provide lucrative opportunities to the market players.

Get Customized Report @ https://www.alliedmarketresearch.com/request-for-customization/4153

Contact:
David Correa
Portland, OR, United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

About Us
Allied Market Research (AMR) is a market research and business-consulting firm of Allied Analytics LLP, based in Portland, Oregon. AMR offers market research reports, business solutions, consulting services, and insights on markets across 11 industry verticals. Adopting extensive research methodologies, AMR is instrumental in helping its clients to make strategic business decisions and achieve sustainable growth in their market domains. We are equipped with skilled analysts and experts, and have a wide experience of working with many Fortune 500 companies and small & medium enterprises.

This release was published on openPR.